The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension

Investigation of the Effects of Ketoconazole on the Pharmacokinetics of Macitentan, a Novel Dual Endothelin Receptor Antagonist, in Healthy Subjects

(2013) Jacob Atsmon et al.   CLINICAL PHARMACOKINETICS

Updated Treatment Algorithm of Pulmonary Arterial Hypertension

(2013) Nazzareno Galiè et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

(2013) Tomás Pulido et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics of Macitentan in Caucasian and Japanese Subjects: The Influence of Ethnicity and Sex

(2013) Shirin Bruderer et al.   PHARMACOLOGY

Single-Dose Pharmacokinetics, Safety, and Tolerability of Macitentan, a New Endothelin Receptor Antagonist, in Subjects with Mild, Moderate or Severe Hepatic Impairment

(2012) Patricia Sidharta et al.   CHEST

Altered expression and signal transduction of endothelin-1 receptors in heritable and idiopathic pulmonary arterial hypertension

(2012) Jun Yu et al.   JOURNAL OF CELLULAR PHYSIOLOGY

The Discovery of N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist

(2012) Martin H. Bolli et al.   JOURNAL OF MEDICINAL CHEMISTRY

Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells

(2012) John Gatfield et al.   PLoS One

Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans

(2012) Shirin Bruderer et al.   XENOBIOTICA

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist

(2011) Shirin Bruderer et al.   AAPS Journal

Macitentan: entry-into-humans study with a new endothelin receptor antagonist

(2011) Patricia N. Sidharta et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

REVIEW: Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension: An Overview

(2010) Shahzad G. Raja   Cardiovascular Therapeutics

Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan

(2009) Oliver Kummer et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension

(2009) A. Lavelle et al.   EUROPEAN RESPIRATORY JOURNAL

Guidelines for the diagnosis and treatment of pulmonary hypertension

(2009) et al.   EUROPEAN RESPIRATORY JOURNAL

Updated Clinical Classification of Pulmonary Hypertension

(2009) Gérald Simonneau et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Does Targeting the Lipophilic Milieu Provide Advantages for an Endothelin Antagonist?

(2009) D. M. Pollock et al.   MOLECULAR INTERVENTIONS

Endothelin receptor antagonists in pulmonary arterial hypertension

(2008) J. Dupuis et al.   EUROPEAN RESPIRATORY JOURNAL

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

(2008) M. Iglarz et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Inflammatory responses after endothelin B (ETB) receptor activation in human monocytes: New evidence for beneficial anti-inflammatory potency of ETB-receptor antagonism

(2008) Uwe R. Juergens et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS